Clinical Trials
3 trialsNCT04199104 2026-05-05
A Study of Pembrolizumab (MK-3475) With or Without Lenvatinib (E7080/MK-7902) as First Line (1L) Intervention in a Programmed Cell Death-ligand 1 (PD-L1) Selected Population With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC) (MK-7902-010) (KEYNOTE-010)
Merck Sharp & Dohme LLC
Phase 3 Completed
NCT05696548 2026-04-09
Nivolumab Plus Lenvatinib Against Anaplastic Thyroid Cancer (NAVIGATION)
National Cancer Center Hospital East
Phase 2 Active not recruiting
NCT07092514 2026-03-17
Lenvatinib 24 mg/Day Versus 10 mg/Day to Treat Symptomatic or Progressive Radioactive Iodine Resistant (RAIR) Differentiated Thyroid Cancer (DTC)
Washington University School of Medicine
Phase 2 Recruiting